Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$166.91M$166.91M+37.5% vs Q3 2020 Net Income-$48.14M-$48.14MN/M vs Q3 2020 EPS Diluted-$0.60-$0.60N/M vs Q3 2020 Operating Income-$34,458,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$133,570,000N/M Margins · derivedOperating margin-20.6%+92.2 pt vs Q3 2020
Net margin-28.8%+133.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 3, 2021 · 34 d after period end